Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
New Business Division	88.68M	94.87M	-	-	-
Inspection Business Division	94.92M	82.61M	75.89M	77.94M	62.94M
Precise Medical Division	143.55M	146.06M	200.91M	188.42M	130.03M
Food Safety Business Division	37.64M	30.63M	39.19M	51.88M	50.40M
Total	364.79M	354.17M	315.98M	318.24M	243.36M

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Asia	364.79M	354.17M	315.98M	317.62M	243.36M
America	-	-	-	618.00K	-
Total	364.79M	354.17M	315.98M	318.24M	243.36M

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 30, 2026

Data Sources Report a data error